Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 746
- Registration Number
- NCT00294723
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 226
- Registration Number
- NCT00154414
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 177
- Registration Number
- NCT00154401
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.